ITPS Canada Achieves NATO Flight Training Europe Accreditation 
Toronto Stock Exchange, TSX Venture Exchange, TSX Alpha Exchange and Montreal Exchange Closed for Labour Day 
Doubleview Appoints Edward Huebert as Vice President, Permitting, Regulatory & Indigenous Relations 
Focus Graphite and C4V to Evaluate Mine-to-Anode Platform Combining Lac Knife Graphite with C4V’s Green Anode Technology 
Spritzer Sparkling Invites Malaysians to ‘Reset Rasa’ This Merdeka, Rediscover the Flavours That Unite Us Jasper Therapeutics to Host Key Opinion Leader Webinar on the Potential of Briquilimab for Chronic Urticaria on October 11, 2023
Company to Discuss Upcoming Briquilimab Clinical Studies in Both Chronic Spontaneous Urticaria and Chronic Inducible…
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE…
Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25
Webcast at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25 SAN DIEGO, Oct. 09, 2023 (GLOBE…
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Topline results expected in 2H 2024 CARMEL, Ind., Oct. 09, 2023 (GLOBE NEWSWIRE) — MBX…
MBX Biosciences Doses First Participant in Phase 1/2 Clinical Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
Topline results expected in 2H 2024 CARMEL, Ind., Oct. 09, 2023 (GLOBE NEWSWIRE) — MBX…
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Mr. Garner brings over 25 years of pharmaceutical industry experience THE WOODLANDS, Texas, Oct. 09,…
Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer
Mr. Garner brings over 25 years of pharmaceutical industry experience THE WOODLANDS, Texas, Oct. 09,…
electroCore to Announce Third Quarter Financial Results on Wednesday, November 8
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
electroCore to Announce Third Quarter Financial Results on Wednesday, November 8
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine…
Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria
First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical…
Jasper Therapeutics Announces IND Clearance for Phase 1b/2a Study of Subcutaneous Briquilimab in Chronic Spontaneous Urticaria
First Patient Expected to be Dosed by Year-end 2023; Early Data Expected by Mid-2024 Clinical…
Aquestive Therapeutics Provides Business Update
Receives positive feedback from FDA on pivotal study protocol for Anaphylm™ (epinephrine) Sublingual Film Reaffirms…
Aquestive Therapeutics Provides Business Update
Receives positive feedback from FDA on pivotal study protocol for Anaphylm™ (epinephrine) Sublingual Film Reaffirms…
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1…
Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
53.3% of patients who received a single dose of 750mg IV imsidolimab achieved GPPPGA 0/1…
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
Morphic Therapeutic to Host Webcast to Present EMERALD-1 Full Data Set
WALTHAM, Mass., Oct. 09, 2023 (GLOBE NEWSWIRE) — Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company…
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Podocyte Exact Morphology Procedure Results Podocyte Exact Morphology Procedure Results ELX-02 treatment improved podocyte foot…
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria
Podocyte Exact Morphology Procedure Results Podocyte Exact Morphology Procedure Results ELX-02 treatment improved podocyte foot…
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)
Topline data results from the STRIDE study are expected in December 2023 IRVINE, Calif., Oct….